东方中科(002819) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 reached ¥597,019,859.74, representing a 60.61% increase year-over-year[7] - The net profit attributable to shareholders was a loss of ¥15,756,008.99, a decline of 163.73% compared to the same period last year[7] - The company reported a 71.66% increase in total revenue for the first nine months of 2022, totaling ¥1,749,858,430.26[12] - Net profit for the period was -$38,489,048.28, a decrease of 168.82% compared to $55,928,500.25 in the previous year, primarily due to seasonal losses in the Wanlihong business[15] - The net profit for the third quarter was -38,489,048.28 CNY, compared to a profit of 55,928,500.25 CNY in the same period last year, indicating a significant decline[36] - The total operating profit was -25,985,918.28 CNY, down from 67,792,100.05 CNY year-over-year[36] - The company reported a total of ¥905,424.49 in non-recurring gains and losses for the current period[8] - The total comprehensive income for the period was -38,489,048.28 CNY, compared to 55,928,500.25 CNY in the previous year[36] Cash Flow and Expenses - The operating cash flow net amount was -¥214,992,222.38, reflecting a significant decrease of 619.45% year-over-year[7] - Cash received from sales of goods and services increased by 72.90% to $1,880,159,305.69 from $1,087,457,177.98, mainly due to increased cash flow from Wanlihong and instrument sales[15] - Cash received from other operating activities rose by 47.92% to $307,928,337.13, attributed to increased cash flow from Wanlihong and higher deposits from bidding agency services[15] - Cash paid to employees surged by 272.90% to $299,487,932.24 from $80,312,568.46, reflecting increased cash flow payments to employees in the Wanlihong business[15] - Cash paid for purchasing goods and services rose by 60.53% to $1,549,554,523.43, mainly due to increased inventory and daily procurement payments[15] - Cash inflow from bank loans increased dramatically by 3600.00% to $37,000,000.00, reflecting a significant rise in bank borrowings during the period[15] - Cash flow from operating activities showed a net outflow of -214,992,222.38 CNY, contrasting with a net inflow of 41,388,053.32 CNY in the previous year[37] - Investment activities resulted in a net cash outflow of -107,998,712.01 CNY, compared to a net inflow of 17,651,491.56 CNY last year[40] Assets and Liabilities - Total assets as of the end of Q3 2022 were ¥5,170,369,729.99, down 1.96% from the end of the previous year[7] - The company's cash and cash equivalents decreased to ¥1,230,429,719.88 from ¥1,548,083,333.35, a decline of about 20.5%[23] - The total assets decreased to ¥5,170,369,729.99 from ¥5,273,831,637.82, a reduction of approximately 1.9%[29] - Total liabilities decreased to ¥933,888,864.86 from ¥957,162,546.16, indicating a decline of about 2.4%[29] - The equity attributable to shareholders decreased to ¥3,796,794,954.88 from ¥3,852,869,981.60, a decrease of approximately 1.5%[29] Research and Development - Research and development expenses surged by 412.30% to ¥135,880,417.45 in the first nine months of 2022[12] - Research and development expenses surged to ¥135,880,417.45, compared to ¥26,523,469.68 in the previous year, reflecting an increase of approximately 412.5%[30] - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[30] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,685, with the largest shareholder, Dongfang Keyi Holdings Group Co., Ltd., holding 24.90%[18] - The company approved the exercise of stock options and the lifting of restrictions on 63,178.5 thousand shares for 27 eligible participants, effective from August 1, 2022[22]